SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
Status:
Unknown status
Trial end date:
2019-09-23
Target enrollment:
Participant gender:
Summary
Chemotherapy treatment with platinum based agents is well noted to cause ototoxicity. It is
the objective of this study to determine the safety and efficacy of SPI-1005 at three dose
levels when delivered orally twice daily for 3 days, surrounding each cycle of platinum
chemotherapy in head and neck or non-small cell lung cancer patients to prevent and treat
chemotherapy induced hearing loss and tinnitus.